Generic Name and Formulations:
Lidocaine 7%, tetracaine 7%; emulsion cream.
Indications for PLIAGLIS:
Local analgesia for superficial dermatological procedures (eg, dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, laser-assisted tattoo removal).
Do not exceed recommended dose or duration. Apply to intact skin prior to procedure; spread evenly and thinly across treatment area using a metal spatula or tongue depressor. Dermal filler inj or facial laser ablation: apply for 20–30 mins. Laser-assisted tattoo removal: apply for 60 mins. Amount (length) to apply: see full labeling.
Avoid overexposure. History of congenital or idiopathic methemoglobinemia: not recommended. G6PD deficiency. Severe hepatic impairment. Pseudocholinesterase deficiency. Avoid contact with eyes, mucous membranes, or areas with a compromised skin barrier (eg, broken or inflamed). Risks of secondary exposure to children and pets; may be toxic. Acutely ill. Debilitated. Elderly. Pregnancy (Cat.B). Nursing mothers.
Topical anesthetic (amide-type + ester-type).
Toxicity may be potentiated by Class I antiarrhythmics (eg, tocainide, mexiletine); caution. Additive effects with other local anesthetics; consider the amount absorbed from all formulations. Increased risk of methemoglobinemia with concomitant methemoglobin-inducing agents (eg, sulfonamides, acetaminophen, acetanilide, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, p- aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, and quinine).
Localized reactions (eg, erythema, skin discoloration, edema), allergic reactions (eg, urticaria, angioedema, bronchospasm, shock).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline